Microbot Liberty Endovascular Robotic System Launched With Full Market Release in the United States

April 13, 2026—Microbot Medical Inc. announced that it has executed a limited market release of the Liberty robotic system for peripheral endovascular procedures.

CUC America Forms Collaborations With Drs. Okuno and Ahmed to Advance MSK Embolization and Build a Scalable OBL Platform

April 11, 2026—CUC America, a provider of advanced vascular and interventional care, announced strategic collaborations with Yuji Okuno, MD, and Osman Ahmed, MD, to accelerate the adoption of musculoskeletal (MSK) embolization and expand access to innovative, minimally invasive therapies across the United States.

ALPHA Registry Studies Okami LOBO Vascular Occlusion System

April 8, 2026—Okami Medical announced the enrollment of the first patient in the ALPHA registry, a prospective, multicenter registry evaluating the safety and effectiveness of the company’s LOBO vascular occlusion system for patients with a variety of peripheral vascular conditions, including arterial hemorrhage and pulmonary arteriovenous malformation.

Embolization, Inc.’s Polymer-Based NED Coil Evaluated in Limited-Market Release 

April 7, 2026—Embolization, Inc. announced findings from the limited-market release of the company’s nitinol enhanced device (NED), which is a radiopaque, polymer-based embolic coil.

Feasibility Trial Begins for Fluidx’s Ultra Embolic Gel in Treatment of Hypervascular Tumors and Blood Vessels

April 2, 2026—Fluidx Medical Technology, Inc. announced that the first patient has been treated with the company’s Ultra embolic gel in a feasibility trial of the device conducted in New Zealand.

Shape Memory Medical Initiates First-in-Human FLAGSHIP Study of False Lumen Embolization System

April 1, 2026—Shape Memory Medical has announced the first patient enrollments in the FLAGSHIP study, a prospective single-arm open-label first-in-human trial evaluating its investigational False Lumen Embolization (FLE) System for treatment of aortic dissection.

Dr. Isabel Newton Named CMO for Boston Scientific’s Interventional Oncology and Embolization Business

February 3, 2026—Isabel Newton, MD, PhD, has been named Chief Medical Officer of Boston Scientific's Interventional Oncology and Embolization business.

Instylla’s Embrace Hydrogel Embolic System Launched 

January 28, 2026—Instylla, Inc., a developer of resorbable embolics for peripheral vascular embolization, announced the completion of the first commercial procedure using the company’s Embrace hydrogel embolic system (HES).

Boston Scientific’s Embold Detachable Coil System Gains CE Mark Approval

January 22, 2026—Boston Scientific announced it has received CE Mark approval for the company’s Embold detachable coil system, which is a new generation of fully retractable embolization coils indicated to obstruct or reduce blood flow in the peripheral vasculature.

Fluidx GPX Embolic Device Pivotal Trial Completes Enrollment 

January 7, 2026—Fluidx Medical Technology, Inc. announced the completion of patient enrollment in the investigational device exemption (IDE) pivotal clinical trial evaluating the company’s GPX embolic device.

Shape Memory Medical’s Impede Embolization Plug Product Family Secures EU MDR Certification

December 22, 2025—Shape Memory Medical Inc. announced that its Impede embolization plug product family, which previously received CE Mark approval under the European Union (EU) Medical Device Directive 93/42/EEC, has received certification as a class III device under the more stringent EU Medical Device Regulation (MDR) 2017/745.

J&J’s TruFill n-BCA Liquid Embolic System Approved to Treat Symptomatic Chronic Subdural Hematoma

December 18, 2025—Johnson & Johnson MedTech announced that the FDA has approved an expanded indication for the company’s TruFill n-Butyl cyanoacrylate (n-BCA) liquid embolic system for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and chronic subdural hematoma (cSDH) as an adjunct to surgery.

Medtronic’s Onyx Liquid Embolic System Approved for Chronic Subdural Hematoma Indication

December 11, 2025—Medtronic announced that the Onyx liquid embolic system (LES)—Onyx 18 and Onyx 34—is now indicated in the United States for embolization of the middle meningeal artery (MMA) as an adjunct to surgery for the treatment of symptomatic subacute or chronic subdural hematoma (SDH).

Okami Medical Names Bill Hykes as CEO and Closes $45M Financing

November 25, 2025—Okami Medical, Inc., a developer of vascular embolization solutions, announced that Drew Hykes was appointed President and CEO of the company, while Bill Hoffman was appointed Chairman of the Board.

CUC and Dr. Yuji Okuno Partner to Expand to Musculoskeletal Embolotherapy in the United States

November 12, 2025—CUC Inc., a provider of health care management and operational support services headquartered in Tokyo, Japan, announced it has signed a Memorandum of Understanding (MOU) with Yuji Okuno, MD, to form a strategic partnership for the expansion of chronic pain treatment business in the United States.

Embolization Inc.’s Polymer-Based NED Coil Used in First Procedure

November 10, 2025—Embolization, Inc. announced that its polymer-based coil intended for arterial and venous embolization in peripheral vasculature was used in its first procedure.

NextBioMedical Begins Pivotal RESORB Trial of Nexsphere-F Microsphere for Genicular Artery Embolization

October 13, 2025—NextBioMedical Co., Ltd., a South Korea–based developer of embolic materials for interventional pain and vascular therapy, announced that the first patient in the United States was enrolled in the company’s RESORB pivotal clinical trial of its Nexsphere-F microsphere, a device for musculoskeletal pain embolization.

Penumbra Launches SwiftSet Coil for Adaptive Neurovascular Embolization

October 9, 2025—Penumbra announced the commercial launch of the SwiftSet coil, a complex embolization coil engineered to provide adaptive vessel wall apposition and smooth, controlled deployment for dense occlusion in small and tortuous neurovascular anatomies.

Penumbra’s SwiftPAC Neuroembolization Coil Receives CE Mark Approval

September 15, 2025—Penumbra Inc. announced it has secured CE Mark approval for its SwiftPAC neuroembolization coil.

Merit’s Embosphere Approved in Europe for Genicular Artery Embolization to Treat Knee Osteoarthritis

September 15, 2025—Merit Medical Systems, Inc. announced that its Embosphere microspheres are now indicated in the European Union for use in genicular artery embolization (GAE) to treat patients with knee osteoarthritis (OA).